172 related articles for article (PubMed ID: 28029328)
1. When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.
Perez K; Clancy TE; Mancias JD; Rosenthal MH; Wolpin BM
J Clin Oncol; 2017 Feb; 35(5):485-489. PubMed ID: 28029328
[TBL] [Abstract][Full Text] [Related]
2. Beyond the Front Line: Emerging Data for Maintenance Therapy in Pancreatic Cancer.
Singh H; Perez K; Wolpin BM; Aguirre AJ
J Clin Oncol; 2021 Oct; 39(29):3199-3206. PubMed ID: 34428095
[No Abstract] [Full Text] [Related]
3. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
4. Timing Is Everything: What Is the Optimal Duration After Chemoradiation for Surgery for Rectal Cancer?
Goodman KA
J Clin Oncol; 2016 Nov; 34(31):3724-3728. PubMed ID: 27601550
[TBL] [Abstract][Full Text] [Related]
5. Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
Nandy N; Dasanu CA
JOP; 2014 Jan; 15(1):46-8. PubMed ID: 24413784
[TBL] [Abstract][Full Text] [Related]
6. What is causing this patient's severe pruritus?
Probst EA; Smith AL; Abad JD
JAAPA; 2020 Jun; 33(6):54-56. PubMed ID: 32452965
[No Abstract] [Full Text] [Related]
7. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
8. Management of diabetes and pancreatic cancer.
Flaherty AM
Oncol Nurs Forum; 2012 Sep; 39(5):440-3. PubMed ID: 22940508
[No Abstract] [Full Text] [Related]
9. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
10. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
11. Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer.
Curigliano G; Criscitiello C
J Clin Oncol; 2017 Aug; 35(23):2600-2603. PubMed ID: 28661760
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Chemotherapy and Radiation Therapy for Inoperable Locally Advanced Non-Small-Cell Lung Cancer.
Rosenzweig KE; Gomez JE
J Clin Oncol; 2017 Jan; 35(1):6-10. PubMed ID: 27870565
[TBL] [Abstract][Full Text] [Related]
13. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Assaf E; Verlinde-Carvalho M; Delbaldo C; Grenier J; Sellam Z; Pouessel D; Bouaita L; Baumgaertner I; Sobhani I; Tayar C; Paul M; Culine S
Oncology; 2011; 80(5-6):301-6. PubMed ID: 21778770
[TBL] [Abstract][Full Text] [Related]
14. Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Wu WC; Chen SC; Su YC; Chuang WL; Chen LT
J Gastroenterol Hepatol; 2004 Jun; 19(6):716-7. PubMed ID: 15151634
[No Abstract] [Full Text] [Related]
15. Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Smyth EN; Bapat B; Ball DE; André T; Kaye JA
Clin Ther; 2015 Jun; 37(6):1301-16. PubMed ID: 25907619
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
Lind PA; Isaksson B; Almström M; Johnsson A; Albiin N; Byström P; Permert J
Acta Oncol; 2008; 47(3):413-20. PubMed ID: 17882555
[TBL] [Abstract][Full Text] [Related]
17. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
[No Abstract] [Full Text] [Related]
18. Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.
Tewari KS
J Clin Oncol; 2019 Jun; 37(17):1449-1454. PubMed ID: 31026210
[No Abstract] [Full Text] [Related]
19. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
